Hansoh Pharma Delivers Double-Digit 2025 Growth as Innovative Drugs Drive Earnings and Pipeline Wins

An announcement from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.

Hansoh Pharmaceutical Group reported strong 2025 results, with revenue rising 22.6% to RMB15.03 billion and profit up 27.1% to RMB5.56 billion, driven by a 30.4% surge in innovative and collaborative medicines, which now account for 82.2% of sales. The board proposed a higher full-year dividend after earnings per share climbed 26.4%, reflecting management’s confidence in cash generation and the sustainability of its innovation-led model.

Operationally, Hansoh advanced a series of key pipeline assets, including its self-developed B7-H3-targeted ADC Risvutatug Rezetecan gaining Breakthrough Therapy status from both U.S. and Chinese regulators for relapsed or refractory osteosarcoma. The company also secured NMPA approval for a second indication of its biologic XINYUE in IgG4-related disease and expanded clinical programs in oncology and immunology, moves that strengthen its positioning in high-value specialty segments and support future growth visibility.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group is a leading innovation-driven drugmaker in mainland China, focused on major disease areas including oncology, anti-infectives, central nervous system, metabolism and immunology. The company has launched seven innovative medicines that generate sales in China, and its portfolio of innovative and collaborative products now underpins the bulk of its revenue and long-term growth strategy.

Average Trading Volume: 8,419,023

Technical Sentiment Signal: Hold

Current Market Cap: HK$197.2B

For an in-depth examination of 3692 stock, go to TipRanks’ Overview page.